Despite near-term sales losses attributable to the upcoming generic erosion of several market-leading drugs, the market for chronic pain therapies will continue to present significant commercial opportunity for drug developers over the next ten years. Key factors driving growth in this market are the increasing prevalence of key population segments, including osteoarthritis pain and chronic low back pain, as well as the unmet need for safer and better-tolerated analgesics. Emerging therapies such as abuse-deterrent opioid reformulations and biologic drugs targeting nerve growth factor (NGF) are expected to have significant implications on overall market dynamics.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 53 country-specific interviews with thought-leading physicians.
Epidemiology: Region-specific prevalence estimates for key chronic pain populations for 2012, 2017, and 2022: arthritic pain (osteoarthritic and rheumatoid), cancer pain (severe, neuropathic, and metastatic bone cancer pain), chronic daily headache, chronic low back pain, fibromyalgia, chronic migraine, painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN).
Emerging therapies: Phase II: 42 drugs; Phase III/preregistration/registered: 15 drugs. Coverage of 5 select preclinical and Phase I products.
Market forecast features: We segment key chronic pain populations in the base year (2012) and forecast population sizes and total chronic pain drug sales for therapies through 2022.